Meto Review

Meto — Provider Profile

Pricing and protocol data sourced from Meto's public website, verified April 2026. We have no commercial relationship with this provider.

Overview

Meto launched in June 2025 with a model that sets it apart from most telehealth weight loss platforms: they accept insurance and handle prior authorizations in-house. Where competitors like Ro, Hims, and Henry Meds operate cash-pay only or provide minimal insurance support, Meto's entire model is built around making metabolic care accessible through existing health coverage.

Founded by Dr. Jossy Onwude — previously Chief Medical & Product Officer at Bold Health — and Dr. Daniel Uba as CMO, Meto positions itself as a full-spectrum metabolic health provider, not just a weight loss prescription service. Their scope includes obesity medicine, type 2 diabetes, prediabetes, metabolic syndrome, PCOS, thyroid conditions, fatty liver disease, and preventive care. The breadth reflects a clinic-style approach rather than a direct-to-consumer drug delivery model.

April 2026 context: Meto is approximately nine months old. There is no established base of independent patient reviews — no Trustpilot ratings, no BBB history, no significant Reddit presence. That is not a red flag for a provider launched mid-2025, but it is information patients should weigh. The insurance-first model is novel and addresses a real barrier; whether the platform delivers on it consistently is something only time and patient volume will reveal.

Pricing and protocol data sourced from Meto's public website, verified April 2026. Patient experience data not available from independent sources as of this date. We have no commercial relationship with this provider.

Medications Offered

• Semaglutide (Ozempic / Wegovy) — GLP-1 receptor agonist; FDA-approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy)
• Tirzepatide (Mounjaro / Zepbound) — Dual GIP/GLP-1 receptor agonist; FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound)
• Phentermine — FDA-approved sympathomimetic appetite suppressant; indicated for short-term weight management

Meto prescribes brand-name medications and uses insurance coverage where applicable. They do not appear to offer compounded versions.

Pricing

Pricing last verified April 2026. We update pricing data monthly.

Important: Meto does not publish self-pay rates on their website. If you are uninsured or your insurance does not cover metabolic services, contact Meto directly to ask about cash-pay options before booking. Do not assume affordability.

For patients with insurance, Meto's model can reduce costs substantially — especially for GLP-1 medications that typically require prior authorization. Meto handling the PA process in-house is a substantive convenience, as prior authorization for weight management medications is time-intensive and often fails without clinical advocacy. See our GLP-1 Prior Authorization Insurance Guide for what the process typically involves.

States Served

State availability is not listed publicly on Meto's website as of April 2026. Verify directly with Meto before beginning the intake process, particularly if you live in a state with stricter telehealth prescribing regulations.

Insurance

Insurance support is Meto's core differentiator. They accept insurance for consultations and handle prior authorization for GLP-1 medications in-house. This is atypical in the telehealth metabolic health space, where most platforms are cash-pay and offer little or no help with insurance coverage.

For patients whose insurance covers obesity medicine, endocrinology, or metabolic health visits, Meto may substantially lower the cost of care compared to cash-pay platforms. However, insurance coverage for GLP-1 medications specifically varies widely by plan, employer, and state. See Does Insurance Cover GLP-1 Medications? for how coverage currently works by plan type.

Consultation Process

Model: Hybrid — both virtual and in-person appointments available, with an async intake assessment prior to scheduling.

1. Complete an online health assessment (clinician-designed intake covering medical history, current medications, weight history, and metabolic conditions)
2. Algorithm-based matching to the appropriate specialist type — endocrinologist, obesity medicine physician, registered dietitian, or metabolic health coach — based on your clinical profile
3. First appointment available within days of completing the assessment
4. Personalized care plan developed at or following the first appointment
5. Ongoing check-ins and care coordination through the platform

The in-person option is notable. Most telehealth weight loss platforms operate virtual-only; Meto's hybrid model means patients who prefer or require face-to-face care have that option, though geographic availability will determine whether this is practical.

Pros

• Insurance-first model. Handling prior authorization in-house addresses one of the most common barriers to affordable GLP-1 access. Most competitors do not offer this.
• Hybrid virtual and in-person care. More flexibility than virtual-only platforms, and better suited to patients managing complex metabolic conditions.
• Specialist matching. The intake-to-specialist matching process connects patients with appropriate clinicians (endocrinology, obesity medicine, dietitian), not a general practitioner ordering medications.
• Broad metabolic health scope. Coverage beyond weight loss includes type 2 diabetes, PCOS, thyroid, fatty liver, and preventive care — relevant for patients managing multiple interrelated conditions.
• Physician leadership with relevant credentials. CEO Dr. Jossy Onwude comes from Bold Health with a combined medical and product background; CMO Dr. Daniel Uba rounds out clinical oversight from day one.

Cons

• No track record. Launched June 2025 — nine months of operation. No published outcomes data, no independent patient review base, no clinical performance history.
• Self-pay pricing is opaque. Patients without insurance or with limited coverage cannot assess affordability without contacting Meto directly. This is a transparency gap.
• State availability is undisclosed. Geographic access is unclear without going through intake, which is inefficient for patients outside major markets.
• Unknown support quality and response time. With no independent reviews to draw on, there is no signal on how Meto handles prescription delays, insurance denials, or platform issues.
• Platform maturity unknown. A nine-month-old company has had limited time to harden its systems, build pharmacy relationships, and work through operational issues at scale.

Best For

Patients with insurance that covers metabolic health services who have been deterred by the prior authorization process at other platforms or clinics. Meto is particularly suited to patients managing multiple metabolic conditions simultaneously — not just weight, but also diabetes, PCOS, or thyroid — who need specialist matching rather than a single-medication telehealth checkout flow.

Patients without insurance, or whose insurance does not cover obesity medicine, should contact Meto for cash-pay rates before assuming this platform is an option.

Editorial Verdict

Meto's insurance-first model solves a real problem. Prior authorization for GLP-1 medications is difficult to clear, and most telehealth platforms offer patients little help with it. A platform that handles PA in-house, matches patients to appropriate specialists, and offers hybrid virtual and in-person care is meaningfully different from the cash-pay prescription pipeline that dominates this space.

The difficulty is that Meto is too new to evaluate on outcomes or patient experience. Nine months of operation is not enough time for an independent review base to develop, and no clinical performance data is available. The core question — does the insurance model work in practice, does the PA process succeed, and is the platform reliable? — is unanswerable right now based on available public information.

For patients with insurance who want to try a differentiated model, Meto is worth evaluating. The intake process is designed to start you with the right specialist type, not a general provider, and the PA support is a substantive benefit if your plan covers metabolic care. For patients who need certainty — established track record, transparent pricing, visible patient reviews — a more established platform is the lower-risk choice at this stage.

For a comparison across GLP-1 telehealth providers, see Best GLP-1 Weight Loss Programs 2026. For a side-by-side look at the two medications Meto prescribes most commonly, see Semaglutide vs. Tirzepatide.

Data Sources

Pricing and protocol information sourced from Meto's official website (meto.co), verified April 2026. Independent patient review data not available as of this verification date — Meto has no established presence on Trustpilot, BBB, or Reddit as of April 2026. Telehealth Ally has no affiliate or commercial relationship with this provider.

Related Content

• Best GLP-1 Weight Loss Programs 2026 — All providers ranked
• Semaglutide vs. Tirzepatide — Clinical comparison of Meto's primary medications
• GLP-1 Prior Authorization Insurance Guide — How PA works and how to navigate it
• Does Insurance Cover GLP-1 Medications? — Coverage by plan type
• GLP-1 Pricing Breakdown by Provider — Side-by-side cost comparison